International SEO for pharmaceutical companies is shaped by one fact: a product can be approved, named, packaged and promoted differently in every country, and what you may say online depends on who is reading. I help pharmaceutical manufacturers, exporters and API suppliers build sites that are visible in each market while staying inside the boundaries their regulatory and medical teams set.
Three audiences, three sets of rules
Most pharma sites serve some mix of these, and the SEO approach is different for each.
| Audience | What they search for | Main constraint |
|---|---|---|
| B2B buyers: distributors, tender teams, other manufacturers | API names, dosage forms, “contract manufacturing”, certifications, “supplier” plus country | Accuracy of regulatory status and certifications per market |
| Healthcare professionals | Generic names, prescribing information, product monographs | Many countries restrict prescription product promotion to verified professionals |
| Patients and the public | Brand names, conditions, side effects, availability | Direct-to-consumer promotion of prescription medicines is prohibited in many countries; the US and New Zealand are notable exceptions |
Because the rules differ, a page that is acceptable in one country may not be in another. I do not decide what is compliant. Your regulatory, medical and legal reviewers do. My job is to build a structure that makes their decisions easy to apply, and to find the search visibility that is available within them.
The brand name problem
The same molecule can be sold under different brand names in different countries, and sometimes the same brand name is used for different products in different countries. People search by the name they know locally. This affects SEO in several ways:
- Each market version of a product page should use the name, strength and pack sizes approved in that market.
- The generic (INN) name is usually the stable link across markets, and is often what professionals and B2B buyers search.
- Products not registered in a market should not appear to be available there. hreflang should only connect pages that are true equivalents, and some products will have no equivalent in some countries.
- Spelling of generic names can differ between regions (for example British and American variants for some medicines), which matters for page titles and copy.
Professional-only content and what Google can see
Where prescribing information must sit behind an “I am a healthcare professional” confirmation or a login, there is a trade-off. Content behind a login is not indexed. Content behind a simple self-declaration interstitial can be indexed in some setups, but whether that is acceptable is a regulatory question for each market, not an SEO one.
What I usually recommend is a clear split: public pages that describe the company, therapeutic areas, manufacturing capabilities, quality systems and corporate information, which can be fully optimised; and professional sections handled according to each market’s rules, with technical settings (noindex, robots rules, gating) applied deliberately rather than by accident. I often find pharma sites where professional content is either fully exposed by mistake or invisible even where it was meant to be public.
Ranking an API or finished-dose exporter with B2B buyers
For manufacturers selling to distributors, tender teams and other companies abroad, especially exporters in countries like Pakistan and India supplying regulated and semi-regulated markets, the SEO work looks more like industrial B2B than consumer health. Buyers search for product names with dosage forms, for manufacturing capabilities, and for proof of quality. Pages that tend to matter:
- A product portfolio with one page per molecule or product family, listing dosage forms and strengths, with registration status described only where your regulatory team confirms it.
- Quality and certification pages naming GMP inspections and approvals you actually hold, with the issuing authority and scope.
- Contract manufacturing and licensing pages explaining capabilities, capacity and the process for partnerships.
- Country or region pages where you have real registrations or distribution partners, rather than one page per country in the world.
- Documentation pages explaining what is available to partners (dossiers, certificates of analysis), with request forms.
Technical and structured data notes for pharma sites
- Organization markup for the company and each legal entity, with correct addresses for real sites only.
- Drug schema exists in schema.org and can describe products where public product pages are appropriate, but Google shows few rich results for it. I use it sparingly and only where accurate.
- MedicalWebPage with reviewed-by and last-reviewed details on patient information pages, reflecting your actual medical review process.
- Version control: product information changes, and outdated PDFs of leaflets often stay indexed for years. I find and handle them.
- Where you collect data through forms or patient programmes, local privacy laws apply (GDPR in the EU and UK, and others). Your legal team should confirm consent wording and data handling.
How work runs with regulatory review
Pharma content goes through medical, legal and regulatory review, and that takes time. I plan SEO work around it: briefs that explain the search need and suggested wording, batched submissions so reviewers see related pages together, and a tracker of approved language that can be reused. Technical fixes that do not change claims (speed, crawling, hreflang, structured data) can usually move faster, so I separate the two streams.
Regulated-sector projects use the same foundations as my other international SEO services, with extra review steps. My case studies show the format of my documentation.
Questions pharmaceutical companies ask about international SEO
Can SEO work at all if we cannot promote prescription products to patients?
Yes. Much of the search demand that matters to pharma companies comes from B2B buyers, partners, professionals, job seekers and investors, and corporate, capability and quality content can be fully optimised. Patient-facing content, where permitted, is a separate decision.
Do you write the medical content?
I write SEO briefs and can draft non-clinical copy such as capability and corporate pages. Clinical and product claims should be written or approved by your medical team. I handle structure, search data and optimisation around their approved text.
Should every country we export to have its own page?
Only where there is something true and specific to say, such as registered products, a local partner or local regulatory detail. A page per country with the same text adds risk and little value.
If your pharmaceutical company operates in several markets and you want the site visible wherever it is allowed to be, contact me for a free audit. You will get findings on structure, gated content indexing and market versions, framed within your regulatory limits.